Phibro Animal Health Corporatio (PAHC) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure
Key numbers
- Adjusted EPS
- $0.85
- Estimate
- $0.73
- Surprise
- +17.1%
- Revenue (period 2026-06-30)
- $396.7M
- Score at report (before → after)
- 6.1 → 6.2/10
Revenue source: xbrl.
How the report landed
Phibro Animal Health Corporatio (PAHC) beat the $0.73 estimate with adjusted EPS of $0.85 — a large 17.1% upside surprise. TrendMatrix's engine moved from Buy (Wait) (6.1/10) to Sell at 6.2/10 after the report.
Coverage in the report window
- Phibro Animal Health Q4 2026 Earnings Call: Complete Transcript — benzinga, 2026-08-27
Where TrendMatrix's rating stands now
TrendMatrix currently rates PAHC Sell at 5.8/10.
4 of the last 4 quarters beat the estimate; this quarter's +17.1% surprise compares with a +18.6% four-quarter average. Next scheduled report: 2026-11-04.
What supports the rating
- Sector modifier (Healthcare): +0.5
- Strong earnings beat streak (4/4)
What argues against it
- Concentration risk — Product: livestock sector
- V7 low-quality RISK_OFF penalty: -0.5 (Q=5.4)
- Leverage penalty (D/E 2.1): -1.5
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $33.93
- Price target
- $38.28
- Stop
- $32.06
- Upside to target
- +12.8%
- Reward-to-risk
- 1.8:1
The stock trades at 14.4× trailing but 8.9× forward earnings — consensus estimates already build in a substantial earnings recovery.
Risk check: RSI 18 — a level conventionally read as oversold.
Model outputs from TrendMatrix’s engine as of 2026-09-25 — shown for context, not personalized investment advice.
PAHC at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Drug Manufacturers - Specialty & Generic
- Market cap
- $1.38B
- P/E (fwd)
- 8.9
- P/E (ttm)
- 14.4
- 52-week range
- $28.25–$60.08
- Off 52-week high
- 43.5%
- RSI (14)
- 18
- Volume vs avg
- 0.50×
- Score today
- 5.8/10